Muscle performance and ankle joint mobility in long-term patients with diabetes-0

Th the patient's shank, link 6 with his/her foot. . 2 DOF* metallic fork to maintain the knee in a fixed position. . 3 DOF* adjustable seat, with bowable back. (a: flexion-extension axis; b: pronation-supination axis; c: internal-external rotation axis). * DOF = Degrees Of Freedom<p><b>Copyright information:</b></p><p>Taken from "Muscle performance and ankle joint mobility in long-term patients with diabetes"</p><p>http://www.biomedcentral.com/1471-2474/9/99</p><p>BMC Musculoskeletal Disorders 2008;9():99-99.</p><p>Published online 4 Jul 2008</p><p>PMCID:PMC2453126.</p><p></p

Muscle performance and ankle joint mobility in long-term patients with diabetes-1

G of a patient: the knee has already been fixed to the metallic fork; the forefoot has already been fixed to link 6 of the device; the rearfoot has been inserted in the mould, and it only needs to be further fixed with Velcro stripes; the shank has already been aligned with link 0 of the device. . Detail of a completed foot fixing.<p><b>Copyright information:</b></p><p>Taken from "Muscle performance and ankle joint mobility in long-term patients with diabetes"</p><p>http://www.biomedcentral.com/1471-2474/9/99</p><p>BMC Musculoskeletal Disorders 2008;9():99-99.</p><p>Published online 4 Jul 2008</p><p>PMCID:PMC2453126.</p><p></p

Experimental setup.

<p>(A) Insoles for the stimulation of cutaneous receptors (from left to right: control insoles, low-density (LD) insoles, linear spacing between nodules: 2.8cm; high-density (HD) insoles, linear spacing between nodules: 1.7cm. (B) Inertial measurement units (IMUs) arrangement.</p

Quantification of foot loading distribution during rowing.

<p>(A) Force, contact area and CoP computed for the instant of peak force as well as over the whole drive phase. Data are referred to the right side of participant 6 (male, 18 years, 84 kg, 1.85 m) while rowing at 18 strokes/min with the control insoles. Profiles have been averaged over the 30 central rowing cycles of the trial (mean and standard deviation are respectively shown with continuous and dashed lines). Vertical dashed lines indicate the instant of peak force (black) and the catch instant (grey). (B) Pressure values detected by each of the 99 sensors of the instrumented insole (darker intensities indicate lower pressure values). Circles denote the sensors which pressure value was greater than the 15 kPa threshold, defining the absence of foot contact, whereas the crossed circle indicates the coordinate of pressure distribution along the foot fore-rear direction.</p

Effect of cutaneous stimulation on foot loading distribution and knee and trunk flexion-extension movements.

<p>Representative graphs referred to the left side of participant 6 (male, 18 years, 84 kg, 1.85 m, 32 strokes/min). With the HD insoles, his force and contact area values at peak force were about 21% and 9% greater than those observed for the LD insoles, and 28% and 14% greater than those observed for the control insoles. Similar effect was found for the HD insoles with respect to the whole drive phase: +22% and +14% of force and contact area with respect to LD insoles, +32% and +17% with respect to control insoles. For each insole and parameter, profiles have been averaged over the 30 central rowing cycles of each trial. Data for different insoles are presented with different traces (Control: thick grey line; LD: thin, black dashed line; HD: thin, black line). Vertical black dashed lines indicate the instant of peak force; vertical grey dashed lines indicate the catch instant.</p

Changes in foot loading with cutaneous stimulation during rowing.

<p>Mean and standard deviation (whiskers) values are shown for (A) the peak force, (B) contact area and (C) the fore-rear CoP position at the instant of peak force. Group data averaged over the drive phase are shown in panels (D), (E) and (F) respectively. Different insoles are represented with different grey intensities (black: Control; dark grey: LD insole; light grey: HD insole), separately for the left and right foot. Asterisks denote statistical significance for pair-wise comparisons with Bonferroni correction at <i>P</i><0.05.</p

DataSheet3_The Burden of Type 1 and Type 2 Diabetes Among Adolescents and Young Adults in 24 Western European Countries, 1990–2019: Results From the Global Burden of Disease Study 2019.docx

Objectives: As little is known about the burden of type 1 (T1DM) and type 2 diabetes (T2DM) in adolescents in Western Europe (WE), we aimed to explore their epidemiology among 10–24 year-olds.Methods: Estimates were retrieved from the Global Burden of Diseases Study (GBD) 2019. We reported counts, rates per 100,000 population, and percentage changes from 1990 to 2019 for prevalence, incidence and years lived with disability (YLDs) of T1DM and T2DM, and the burden of T2DM in YLDs attributable to high body mass index (HBMI), for 24 WE countries.Results: In 2019, prevalence and disability estimates were higher for T1DM than T2DM among 10–24 years old adolescents in WE. However, T2DM showed a greater increase in prevalence and disability than T1DM in the 30 years observation period in all WE countries. Prevalence increased with age, while only minor differences were observed between sexes.Conclusion: Our findings highlight the substantial burden posed by DM in WE among adolescents. Health system responses are needed for transition services, data collection systems, education, and obesity prevention.</p

DataSheet1_The Burden of Type 1 and Type 2 Diabetes Among Adolescents and Young Adults in 24 Western European Countries, 1990–2019: Results From the Global Burden of Disease Study 2019.PDF

Objectives: As little is known about the burden of type 1 (T1DM) and type 2 diabetes (T2DM) in adolescents in Western Europe (WE), we aimed to explore their epidemiology among 10–24 year-olds.Methods: Estimates were retrieved from the Global Burden of Diseases Study (GBD) 2019. We reported counts, rates per 100,000 population, and percentage changes from 1990 to 2019 for prevalence, incidence and years lived with disability (YLDs) of T1DM and T2DM, and the burden of T2DM in YLDs attributable to high body mass index (HBMI), for 24 WE countries.Results: In 2019, prevalence and disability estimates were higher for T1DM than T2DM among 10–24 years old adolescents in WE. However, T2DM showed a greater increase in prevalence and disability than T1DM in the 30 years observation period in all WE countries. Prevalence increased with age, while only minor differences were observed between sexes.Conclusion: Our findings highlight the substantial burden posed by DM in WE among adolescents. Health system responses are needed for transition services, data collection systems, education, and obesity prevention.</p

DataSheet2_The Burden of Type 1 and Type 2 Diabetes Among Adolescents and Young Adults in 24 Western European Countries, 1990–2019: Results From the Global Burden of Disease Study 2019.docx

Objectives: As little is known about the burden of type 1 (T1DM) and type 2 diabetes (T2DM) in adolescents in Western Europe (WE), we aimed to explore their epidemiology among 10–24 year-olds.Methods: Estimates were retrieved from the Global Burden of Diseases Study (GBD) 2019. We reported counts, rates per 100,000 population, and percentage changes from 1990 to 2019 for prevalence, incidence and years lived with disability (YLDs) of T1DM and T2DM, and the burden of T2DM in YLDs attributable to high body mass index (HBMI), for 24 WE countries.Results: In 2019, prevalence and disability estimates were higher for T1DM than T2DM among 10–24 years old adolescents in WE. However, T2DM showed a greater increase in prevalence and disability than T1DM in the 30 years observation period in all WE countries. Prevalence increased with age, while only minor differences were observed between sexes.Conclusion: Our findings highlight the substantial burden posed by DM in WE among adolescents. Health system responses are needed for transition services, data collection systems, education, and obesity prevention.</p

DataSheet4_The Burden of Type 1 and Type 2 Diabetes Among Adolescents and Young Adults in 24 Western European Countries, 1990–2019: Results From the Global Burden of Disease Study 2019.docx

Objectives: As little is known about the burden of type 1 (T1DM) and type 2 diabetes (T2DM) in adolescents in Western Europe (WE), we aimed to explore their epidemiology among 10–24 year-olds.Methods: Estimates were retrieved from the Global Burden of Diseases Study (GBD) 2019. We reported counts, rates per 100,000 population, and percentage changes from 1990 to 2019 for prevalence, incidence and years lived with disability (YLDs) of T1DM and T2DM, and the burden of T2DM in YLDs attributable to high body mass index (HBMI), for 24 WE countries.Results: In 2019, prevalence and disability estimates were higher for T1DM than T2DM among 10–24 years old adolescents in WE. However, T2DM showed a greater increase in prevalence and disability than T1DM in the 30 years observation period in all WE countries. Prevalence increased with age, while only minor differences were observed between sexes.Conclusion: Our findings highlight the substantial burden posed by DM in WE among adolescents. Health system responses are needed for transition services, data collection systems, education, and obesity prevention.</p